Zyversa Therapeutics Stock Cash And Equivalents
| ZVSADelisted Stock | 0.15 0.01 6.25% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess ZyVersa Therapeutics' long-term financial health and intrinsic value.
ZyVersa |
ZyVersa Therapeutics Company Cash And Equivalents Analysis
ZyVersa Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, ZyVersa Therapeutics has 0.0 in Cash And Equivalents. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
ZyVersa Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ZyVersa Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ZyVersa Therapeutics could also be used in its relative valuation, which is a method of valuing ZyVersa Therapeutics by comparing valuation metrics of similar companies.ZyVersa Therapeutics is currently under evaluation in cash and equivalents category among its peers.
ZyVersa Fundamentals
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (2.41 M) | ||||
| Shares Outstanding | 4.87 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 7.28 % | ||||
| Number Of Shares Shorted | 359.25 K | ||||
| Price To Book | 0.09 X | ||||
| EBITDA | (9.14 B) | ||||
| Net Income | (9.41 M) | ||||
| Total Debt | 12.08 M | ||||
| Book Value Per Share | 3.17 X | ||||
| Cash Flow From Operations | (7.56 M) | ||||
| Short Ratio | 0.25 X | ||||
| Earnings Per Share | (4.68) X | ||||
| Target Price | 20.0 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 707.14 K | ||||
| Total Asset | 20.6 M | ||||
| Retained Earnings | (112.63 B) | ||||
| Working Capital | (9.52 M) | ||||
| Net Asset | 20.6 M |
About ZyVersa Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ZyVersa Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ZyVersa Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ZyVersa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in ZyVersa Stock
If you are still planning to invest in ZyVersa Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ZyVersa Therapeutics' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |